Abstract
Taking into account that compounds bearing a thiazolyl, pyridyl and indolyl, moieties possess a wide spectrum of biological activities which is related to their capacity to transfer electrons and to scavenge reactive oxygen species (ROS), we synthesized some new heterocyclic aryl acetic acids and the corresponding acetohydroxamic acids and we explored their ability to inhibit soybean lipoxygenase, to present antioxidant and anti-inflammatory activities as well as to present serine proteases inhibition. The compounds were found to strongly inhibit lipid peroxidation. and to decrease in vivo the carrageenin induced rat paw edema (28-56%). Compound 1i possesses the highest decrease 56%, in vivo. The tested derivatives presented interesting inhibitory activity on soybean lipoxygenase. Compound 5ii showed significant in vitro inhibition on trypsin (IC50 87μM). The results are discussed in terms of structural and physicochemical characteristics of the compounds. The structures of the synthesized compounds were confirmed by spectral and elemental analysis. Their lipophilicity is experimentally determined by RPTLC method.
Keywords: Antioxidant agents, anti-inflammatory agents, lipoxygenase inhibitors, serine protease inhibitors, heterocyclic aryl -acetic, hydroxamic acids
Medicinal Chemistry
Title: Heterocyclic Aryl(Phenyl)Acetic Acid and Aryl Acetohydroxamic Acids as Antiinflammatory -Antioxidant Agents and Inhibitors of Lipoxygenase and Serine Proteases
Volume: 3 Issue: 5
Author(s): A. Michaelidou, D. Hadjipavlou-Litina, I. Matsini and E. Tsitsogianni
Affiliation:
Keywords: Antioxidant agents, anti-inflammatory agents, lipoxygenase inhibitors, serine protease inhibitors, heterocyclic aryl -acetic, hydroxamic acids
Abstract: Taking into account that compounds bearing a thiazolyl, pyridyl and indolyl, moieties possess a wide spectrum of biological activities which is related to their capacity to transfer electrons and to scavenge reactive oxygen species (ROS), we synthesized some new heterocyclic aryl acetic acids and the corresponding acetohydroxamic acids and we explored their ability to inhibit soybean lipoxygenase, to present antioxidant and anti-inflammatory activities as well as to present serine proteases inhibition. The compounds were found to strongly inhibit lipid peroxidation. and to decrease in vivo the carrageenin induced rat paw edema (28-56%). Compound 1i possesses the highest decrease 56%, in vivo. The tested derivatives presented interesting inhibitory activity on soybean lipoxygenase. Compound 5ii showed significant in vitro inhibition on trypsin (IC50 87μM). The results are discussed in terms of structural and physicochemical characteristics of the compounds. The structures of the synthesized compounds were confirmed by spectral and elemental analysis. Their lipophilicity is experimentally determined by RPTLC method.
Export Options
About this article
Cite this article as:
Michaelidou A., Hadjipavlou-Litina D., Matsini I. and Tsitsogianni E., Heterocyclic Aryl(Phenyl)Acetic Acid and Aryl Acetohydroxamic Acids as Antiinflammatory -Antioxidant Agents and Inhibitors of Lipoxygenase and Serine Proteases, Medicinal Chemistry 2007; 3 (5) . https://dx.doi.org/10.2174/157340607781745456
DOI https://dx.doi.org/10.2174/157340607781745456 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Determinants of 25-Hydroxyvitamin D Concentrations in Infants and Toddlers
Current Nutrition & Food Science Targets to Tackle – The Pathophysiology of the Disease
Current Drug Targets The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease
Current Pharmaceutical Design Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer
Current Topics in Medicinal Chemistry Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets Limitations and Potential Clinical Application on Contrast Echocardiography
Current Cardiology Reviews Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study
Infectious Disorders - Drug Targets Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design New Trends in Dual 5-LOX / COX Inhibition
Current Medicinal Chemistry Oxidative stress and myocarditis
Current Pharmaceutical Design On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research